Design and characterization of non-phosphopeptide inhibitors for Src family SH2 domains

被引:12
|
作者
Park, SH
Won, J
Lee, KH
机构
[1] Inha Univ, Dept Chem, Inchon 402751, South Korea
[2] Mogam Biotechnol Res Inst, Signal Transduct Lab, Yongin 449910, Kyunggi Do, South Korea
关键词
D O I
10.1016/S0960-894X(02)00523-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The development of novel non-phosphopeptide inhibitors for the Src family SH2 domain is described. Several commercially available hydroxyl aromatic acids have been appended off the N-terminus of pYEEIE and the potent phosphopeptide inhibitors of GST-Lck-SH2 were identified via ELISA. The most potent inhibitor, caffeic acid-pYEEIE, exhibited approximately 30-fold more binding activity than Ac-pYEEIE. Non-phosphopeptides were synthesized by replacing phosphotyrosine of caffeic acid-pYEEIE with tyrosine or 3,4-dihydroxyphenylalanine (DOPA). Caffeic acid-DOPA-EEIE that did not contain phosphotyrosine and its isosteres exhibited less than 20 times decreased binding affinity for GST-Lck-SH2 than Ac-pYEEIE. Moreover, it had a similar binding affinity for the GST-Lck-SH2, GST-Src-SH2, and GST-Fyn-SH2 domains. This study showed that the pY-1 positions of the phosphopeptide inhibitors and of the non-phosphopeptide inhibitors played an important role in the binding for the SH2 domain and that the non-phosphopeptide inhibitor must be a new lead in the development of SH2 inhibitors. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:2711 / 2714
页数:4
相关论文
共 50 条
  • [11] Identification and characterization of a large family of superbinding bacterial SH2 domains
    Tomonori Kaneko
    Peter J. Stogios
    Xiang Ruan
    Courtney Voss
    Elena Evdokimova
    Tatiana Skarina
    Amy Chung
    Xiaoling Liu
    Lei Li
    Alexei Savchenko
    Alexander W. Ensminger
    Shawn S.-C. Li
    Nature Communications, 9
  • [12] Non-phosphopeptide inhibitor for Lck SH2 domain:: Solid-phase synthesis and structure activity relationship of rosmarinic acid analogs
    Kang, SH
    Park, SH
    Shim, HS
    Lee, KH
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2003, 24 (05): : 664 - 666
  • [13] SEQUENCE SPECIFICITY OF THE SRC FAMILY KINASE SH2 DOMAINS AS REVEALED BY A COMBINATORIAL LIBRARY APPROACH
    Tan, P.
    Pei, D.
    BIOPOLYMERS, 2009, 92 (04) : 339 - 339
  • [14] Alternative modes of tyrosyl phosphopeptide binding to a Src family SH2 domain: Implications for regulation of tyrosine kinase activity
    Ladbury, JE
    Hensmann, M
    Panayotou, G
    Campbell, ID
    BIOCHEMISTRY, 1996, 35 (34) : 11062 - 11069
  • [15] Structure-based design and synthesis of a novel class of Src SH2 inhibitors
    Buchanan, JL
    Bohacek, RS
    Luke, GP
    Hatada, M
    Lu, XD
    Dalgarno, DC
    Narula, SS
    Yuan, R
    Holt, DA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (16) : 2353 - 2358
  • [16] CHARACTERIZATION OF PROTEIN-TYROSINE-PHOSPHATASE SH-PTP2 - STUDY OF PHOSPHOPEPTIDE SUBSTRATES AND POSSIBLE REGULATORY ROLE OF SH2 DOMAINS
    DECHERT, U
    ADAM, M
    HARDER, KW
    CLARKLEWIS, I
    JIRIK, F
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (08) : 5602 - 5611
  • [17] An investigation of phosphopeptide binding to SH2 domain
    Lee, JK
    Moon, T
    Chi, MW
    Song, JS
    Choi, YS
    Yoon, CN
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 306 (01) : 225 - 230
  • [18] Inhibitors of the Src SH2 domain and Src tyrosine kinase as potential anticancer drugs
    Tranter, D
    DRUG DISCOVERY TODAY, 2001, 6 (04) : 215 - 216
  • [19] Dissection of the energetic coupling across the Src SH2 domain-tyrosyl phosphopeptide interface
    Lubman, OY
    Waksman, G
    JOURNAL OF MOLECULAR BIOLOGY, 2002, 316 (02) : 291 - 304
  • [20] Inhibitors to the Src SH2 domain: A lesson in structure-thermodynamic correlation in drug design
    Henriques, DA
    Ladbury, JE
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 390 (02) : 158 - 168